COVID-19 Resources
COVID-19
RMS has established this critical information and insights page to provide the latest COVID-19 developments. As the situation continues to evolve, our goal is to help you strengthen your understanding and manage the impacts from COVID-19. See below for our latest risk assessment reports, COVID-19 blogs, webinar series, RMS media coverage, and additional resources to get you up to speed on the risk surrounding COVID-19 and how to respond.
Explore COVID-19 Expertise from RMS
Dexamethasone: The First Life-Saving Drug for Very Sick COVID-19…
In the history of medicine, there have been many major discoveries that were made serendipitously. Drugs which have been developed to treat one illness have proven effective for quite another. This apparently haphazard nature of medical discovery gives rise to what can appear to be a random walk of medical progress, a phenomenon which is captured in the RMS LifeRisks longevity model. Dexamethasone belongs to a class of medicines known as corticosteroids,…
RMS Speaks With BBC
Chief Research Officer Robert Muir-Wood covers global…
ICMIF Webinar
RMS and Willis Re discuss the insurance implications…
Learn More
RMS COVID-19 Pandemic Projections
Access 3 to 6 month projections to support longer term decision-making.
COVID-19 FAQ
Read about the frequently asked questions surrounding the coronavirus.
Coronavirus Will Cost Businesses Billions
Two years ago Munich Re, the reinsurance giant, tried to start underwriting a new kind of insurance — one that would make a company whole if its business tanked in an epidemic. For months, there were no takers.
Access Information About RMS LifeRisks
Bring an integrated view of mortality shock and longevity trend risks underpinned by detailed medical research into your life, annuity, and pensions portfolios.
Integrated Platform
LifeRisks is a cloud-based software platform that delivers the models and data to perform portfolio specific analytics for the management of mortality and longevity risk.
Ready to Work Smarter?
